• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中文译文:中国教学医院碳青霉烯类耐药医院感染的临床危险因素和结局:2013 年至 2020 年的回顾性研究。

Clinical risk factors and outcomes of carbapenem-resistant nosocomial infections in a Chinese teaching hospital: a retrospective study from 2013 to 2020.

机构信息

Department of Laboratory Medicine, Tianjin Medical University General Hospital, Tianjin, China.

Tianjin Medical University General Hospital, Tianjin, China.

出版信息

Microbiol Spectr. 2024 Jul 2;12(7):e0422823. doi: 10.1128/spectrum.04228-23. Epub 2024 May 30.

DOI:10.1128/spectrum.04228-23
PMID:38814065
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11218472/
Abstract

The emergence of carbapenem-resistant strains poses a considerable challenge to global public health, and little is known about carbapenemase-producing strains in Tianjin, China. This study aimed to investigate the risk factors for infections with carbapenem-resistant (CREC) strains. This retrospective case-control study was conducted at a tertiary teaching hospital. A total of 134 CREC clinical isolates were collected from the General Hospital of Tianjin Medical University between 2013 and 2020. The control group was selected at a ratio of 1:1 from patients with nosocomial carbapenem-susceptible infection. Risk factors for nosocomial CREC infection and clinical outcomes were analyzed using univariate and multivariate analyses. Multivariate analysis revealed that cephalosporin exposure (odd ratio OR = 2.01), carbapenem exposure (OR = 1.96), glucocorticoid exposure (OR = 32.45), and surgical history (OR = 3.26) were independent risk factors for CREC infection. The in-hospital mortality rate in the CREC group was 29.1%, and age >65 years (OR = 3.19), carbapenem exposure (OR = 3.54), and central venous catheter insertion (OR = 4.19) were independent risk factors for in-hospital mortality in patients with CREC infections. Several factors were identified in the development of nosocomial CREC infections. The CREC isolates were resistant to most antibiotics. Reducing CREC mortality requires a comprehensive consideration of appropriate antibiotic use, underlying diseases, and invasive procedures.IMPORTANCE is an opportunistic pathogen that causes severe hospital-acquired infections. The spread of carbapenem-resistant is a global threat to public health, and only a few antibiotics are effective against these infections. Consequently, these infections are usually associated with poor prognosis and high mortality. Therefore, understanding the risk factors associated with the causes and outcomes of these infections is crucial to reduce their incidence and initiate appropriate therapies. In our study, several factors were found to be involved in nosocomial carbapenem-resistant (CREC) infections, and CREC isolates were resistant to most antibiotics. Reducing CREC mortality needs a comprehensive consideration of whether antibiotics are used appropriately, underlying diseases, and invasive interventions. These findings provide valuable evidence for the development of anti-infective therapy, infection prevention, and control of CREC-positive infections.

摘要

碳青霉烯类耐药 (CREC) 菌株的出现对全球公共卫生构成了相当大的挑战,而中国天津产碳青霉烯酶 (CRE) 菌株的情况知之甚少。本研究旨在探讨耐碳青霉烯类 (CRE) 感染的危险因素。这项回顾性病例对照研究在一家三级教学医院进行。共从 2013 年至 2020 年期间从天津医科大学总医院收集了 134 株 CREC 临床分离株。对照组是从医院获得性碳青霉烯类敏感 (CREC) 感染患者中以 1:1 的比例选择的。使用单因素和多因素分析分析了医院获得性 CREC 感染和临床结果的危险因素。多因素分析显示,头孢菌素暴露(比值比 [OR] = 2.01)、碳青霉烯类暴露(OR = 1.96)、糖皮质激素暴露(OR = 32.45)和手术史(OR = 3.26)是 CREC 感染的独立危险因素。CREC 组的院内死亡率为 29.1%,年龄>65 岁(OR = 3.19)、碳青霉烯类暴露(OR = 3.54)和中心静脉导管插入(OR = 4.19)是 CREC 感染患者院内死亡的独立危险因素。在医院获得性 CREC 感染的发生中确定了几个因素。CREC 分离株对大多数抗生素具有耐药性。降低 CREC 死亡率需要综合考虑适当使用抗生素、基础疾病和侵入性操作。

重要的是一种机会性病原体,可引起严重的医院获得性感染。碳青霉烯类耐药 (CRE) 的传播对全球公共卫生构成威胁,只有少数抗生素对这些感染有效。因此,这些感染通常与不良预后和高死亡率相关。因此,了解导致这些感染的原因和结果的危险因素对于降低其发病率和启动适当的治疗至关重要。在我们的研究中,发现了几个因素与医院获得性碳青霉烯类耐药 (CREC) 感染有关,并且 CREC 分离株对大多数抗生素具有耐药性。降低 CREC 死亡率需要综合考虑是否适当使用抗生素、基础疾病和侵入性干预。这些发现为制定抗感染治疗、感染预防和控制 CREC 阳性感染的策略提供了有价值的证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d040/11218472/66f502e57cfd/spectrum.04228-23.f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d040/11218472/e5d40f14f08e/spectrum.04228-23.f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d040/11218472/ca0444703885/spectrum.04228-23.f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d040/11218472/66f502e57cfd/spectrum.04228-23.f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d040/11218472/e5d40f14f08e/spectrum.04228-23.f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d040/11218472/ca0444703885/spectrum.04228-23.f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d040/11218472/66f502e57cfd/spectrum.04228-23.f003.jpg

相似文献

1
Clinical risk factors and outcomes of carbapenem-resistant nosocomial infections in a Chinese teaching hospital: a retrospective study from 2013 to 2020.中文译文:中国教学医院碳青霉烯类耐药医院感染的临床危险因素和结局:2013 年至 2020 年的回顾性研究。
Microbiol Spectr. 2024 Jul 2;12(7):e0422823. doi: 10.1128/spectrum.04228-23. Epub 2024 May 30.
2
Risk factors and molecular characterization of carbapenem resistant Escherichia coli recovered from a tertiary hospital in Fujian, China from 2021 to 2023.2021 年至 2023 年期间从中国福建一家三级医院回收的耐碳青霉烯类大肠埃希菌的危险因素和分子特征。
BMC Microbiol. 2024 Sep 28;24(1):374. doi: 10.1186/s12866-024-03525-9.
3
Risk factors and medical costs for healthcare-associated carbapenem-resistant Escherichia coli infection among hospitalized patients in a Chinese teaching hospital.中国一家教学医院住院患者中医疗保健相关耐碳青霉烯类大肠杆菌感染的危险因素及医疗费用
BMC Infect Dis. 2017 Jan 17;17(1):82. doi: 10.1186/s12879-016-2176-9.
4
Population genomic analysis reveals the emergence of high-risk carbapenem-resistant Escherichia coli among ICU patients in China.群体基因组分析揭示了中国重症监护病房患者中耐碳青霉烯类高风险大肠杆菌的出现。
J Infect. 2023 Apr;86(4):316-328. doi: 10.1016/j.jinf.2023.02.004. Epub 2023 Feb 9.
5
Emergence and transmission of New Delhi metallo-beta-lactamase-5-producing Escherichia coli Sequence Type 361 in a Tertiary Hospital in South Korea.韩国一家三级医院中产生并传播的携带新德里金属β-内酰胺酶-5 的大肠埃希菌序列型 361。
J Clin Lab Anal. 2020 Feb;34(2):e23041. doi: 10.1002/jcla.23041. Epub 2019 Sep 20.
6
Impact of carbapenem heteroresistance among clinical isolates of invasive Escherichia coli in Chongqing, southwestern China.中国西南部重庆市侵袭性大肠埃希菌临床分离株中碳青霉烯类异质性耐药的影响。
Clin Microbiol Infect. 2015 May;21(5):469.e1-10. doi: 10.1016/j.cmi.2014.12.013. Epub 2014 Dec 26.
7
Carbapenem-resistant Enterobacter cloacae complex in a tertiary Hospital in Northeast China, 2010-2019.2010-2019 年中国东北地区一家三甲医院耐碳青霉烯肠杆菌科细菌的流行情况
BMC Infect Dis. 2021 Jun 26;21(1):611. doi: 10.1186/s12879-021-06250-0.
8
The Rising Tide of Antibiotic Resistance: A Study on Extended-Spectrum Beta-Lactamase and Carbapenem-Resistant Escherichia coli and Klebsiella pneumoniae.抗生素耐药性的兴起:对产超广谱β-内酰胺酶和碳青霉烯类耐药的大肠埃希菌和肺炎克雷伯菌的研究。
J Clin Lab Anal. 2024 May;38(10):e25081. doi: 10.1002/jcla.25081. Epub 2024 Jun 17.
9
Characterization of Carbapenem-Resistant Enterobacteriaceae Clinical Isolates in Al Thawra University Hospital, Sana'a, Yemen.也门萨那 Al Thawra 大学医院耐碳青霉烯肠杆菌科临床分离株的特征。
Microb Drug Resist. 2020 Mar;26(3):211-217. doi: 10.1089/mdr.2018.0443. Epub 2019 Aug 9.
10
Systematic review of carbapenem-resistant Enterobacteriaceae causing neonatal sepsis in China.中国碳青霉烯类耐药肠杆菌科引起新生儿败血症的系统评价。
Ann Clin Microbiol Antimicrob. 2019 Nov 14;18(1):36. doi: 10.1186/s12941-019-0334-9.

引用本文的文献

1
Joint surveillance and correlation analysis of antimicrobial resistance and consumption of seven targeted bacteria, 2017-2023.2017 - 2023年七种目标细菌的耐药性与消耗量联合监测及相关性分析
Sci Rep. 2025 Aug 26;15(1):31381. doi: 10.1038/s41598-025-16957-8.
2
Seven-year change of prevalence, clinical risk factors, and mortality of patients with carbapenem-resistant bloodstream infection in a Chinese teaching hospital: a case-case-control study.中国一家教学医院中耐碳青霉烯类血流感染患者的患病率、临床危险因素及死亡率的七年变化:一项病例-病例对照研究
Front Microbiol. 2025 Mar 19;16:1531984. doi: 10.3389/fmicb.2025.1531984. eCollection 2025.

本文引用的文献

1
Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017-2019.肠杆菌科中 ESBLs 和碳青霉烯酶的发生率以及全球分离的铜绿假单胞菌中的碳青霉烯酶:来自 ATLAS 2017-2019 的结果。
J Antimicrob Chemother. 2023 Jul 5;78(7):1606-1615. doi: 10.1093/jac/dkad127.
2
Risk Factors for Carbapenem-Resistant Clinical Treatment Failure.碳青霉烯类耐药临床治疗失败的危险因素。
Microbiol Spectr. 2023 Feb 14;11(1):e0264722. doi: 10.1128/spectrum.02647-22. Epub 2023 Jan 9.
3
Case-case-control study of risk factors for carbapenem-resistant Enterobacterales infections among hospitalized patients.
住院患者中耐碳青霉烯类肠杆菌科细菌感染危险因素的病例-病例对照研究
Antimicrob Steward Healthc Epidemiol. 2022 Jul 14;2(1):e118. doi: 10.1017/ash.2022.244. eCollection 2022.
4
A Nationwide Plasmidome Surveillance in Thailand Reveals a Limited Variety of New Delhi Metallo-β-Lactamase-Producing Carbapenem-Resistant Clones and Spreading Plasmids.泰国全国范围的质粒组监测揭示了有限数量的新德里金属β-内酰胺酶产生碳青霉烯类耐药克隆和传播质粒。
J Clin Microbiol. 2022 Dec 21;60(12):e0108022. doi: 10.1128/jcm.01080-22. Epub 2022 Nov 29.
5
ST11 Carbapenem-Resistant Clone Harboring Replaced a Clone in a Tertiary Hospital in China.携带碳青霉烯耐药性的ST11克隆在中国一家三级医院取代了另一个克隆。
Antibiotics (Basel). 2022 Oct 7;11(10):1373. doi: 10.3390/antibiotics11101373.
6
Prevalence and risk factors of carbapenem-resistant positivity by active screening in intensive care units in the Henan Province of China: A multi-center cross-sectional study.中国河南省重症监护病房主动筛查碳青霉烯类耐药菌阳性的患病率及危险因素:一项多中心横断面研究
Front Microbiol. 2022 Sep 14;13:894341. doi: 10.3389/fmicb.2022.894341. eCollection 2022.
7
Transmission of Carbapenem-Resistant Klebsiella pneumoniae in US Hospitals.耐碳青霉烯类肺炎克雷伯菌在美国医院的传播。
Clin Infect Dis. 2023 Jan 13;76(2):229-237. doi: 10.1093/cid/ciac791.
8
Nationwide surveillance in Thailand revealed genotype-dependent dissemination of carbapenem-resistant .泰国的全国性监测显示,碳青霉烯类耐药菌的传播存在基因型依赖性。
Microb Genom. 2022 Apr;8(4). doi: 10.1099/mgen.0.000797.
9
Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Bloodstream Infection: a Systematic Review and Meta-Analysis.头孢他啶-阿维巴坦治疗碳青霉烯类耐药血流感染的疗效和安全性:系统评价和荟萃分析。
Microbiol Spectr. 2022 Apr 27;10(2):e0260321. doi: 10.1128/spectrum.02603-21. Epub 2022 Apr 4.
10
Synergistic Antibacterial Effects of Meropenem in Combination with Aminoglycosides against Carbapenem-Resistant Harboring and .美罗培南与氨基糖苷类药物联合应用对携带和产碳青霉烯酶的耐碳青霉烯菌的协同抗菌作用。 (你提供的原文似乎不完整,存在部分缺失内容,但按要求尽量准确翻译了现有内容)
Antibiotics (Basel). 2021 Aug 23;10(8):1023. doi: 10.3390/antibiotics10081023.